Cargando…

B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children

BACKGROUND: SLE is likely triggered by gene–environment interactions. We have shown that most SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enhancer function in lymphocytes, suggesting genetic risk is exerted through altered gene regulation. Data r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui-Yuen, Joyce, Jiang, Kaiyu, Malkiel, Susan, Eberhard, Barbara Anne, Walters, Heather, Diamond, Betty, Jarvis, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201247/
https://www.ncbi.nlm.nih.gov/pubmed/37202122
http://dx.doi.org/10.1136/lupus-2023-000921
_version_ 1785045226400776192
author Hui-Yuen, Joyce
Jiang, Kaiyu
Malkiel, Susan
Eberhard, Barbara Anne
Walters, Heather
Diamond, Betty
Jarvis, James
author_facet Hui-Yuen, Joyce
Jiang, Kaiyu
Malkiel, Susan
Eberhard, Barbara Anne
Walters, Heather
Diamond, Betty
Jarvis, James
author_sort Hui-Yuen, Joyce
collection PubMed
description BACKGROUND: SLE is likely triggered by gene–environment interactions. We have shown that most SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enhancer function in lymphocytes, suggesting genetic risk is exerted through altered gene regulation. Data remain scarce on how epigenetic variance contributes to disease risk in paediatric SLE (pSLE). We aim to identify differences in epigenetically regulated chromatin architecture in treatment-naive patients with pSLE compared with healthy children. METHODS: Using the assay for transposase-accessible chromatin with sequencing (ATACseq), we surveyed open chromatin in 10 treatment-naive patients with pSLE, with at least moderate disease severity, and 5 healthy children. We investigated whether regions of open chromatin unique to patients with pSLE demonstrate enrichment for specific transcriptional regulators, using standard computational approaches to identify unique peaks and a false discovery rate of <0.05. Further analyses for histone modification enrichment and variant calling were performed using bioinformatics packages in R and Linux. RESULTS: We identified 30 139 differentially accessible regions (DAR) unique to pSLE B cells; 64.3% are more accessible in pSLE than healthy children. Many DAR are found in distal, intergenic regions and enriched for enhancer histone marks (p=0.027). B cells from adult patients with SLE contain more regions of inaccessible chromatin than those in pSLE. In pSLE B cells, 65.2% of the DAR are located within or near known SLE haplotypes. Further analysis revealed enrichment of transcription factor binding motifs within these DAR that may regulate genes involved in pro-inflammatory responses and cellular adhesion. CONCLUSIONS: We demonstrate an epigenetically distinct profile in pSLE B cells when compared with healthy children and adults with lupus, indicating that pSLE B cells are predisposed for disease onset/development. Increased chromatin accessibility in non-coding genomic regions controlling activation of inflammation suggest that transcriptional dysregulation by regulatory elements controlling B cell activation plays an important role in pSLE pathogenesis.
format Online
Article
Text
id pubmed-10201247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102012472023-05-23 B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children Hui-Yuen, Joyce Jiang, Kaiyu Malkiel, Susan Eberhard, Barbara Anne Walters, Heather Diamond, Betty Jarvis, James Lupus Sci Med Genetics BACKGROUND: SLE is likely triggered by gene–environment interactions. We have shown that most SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enhancer function in lymphocytes, suggesting genetic risk is exerted through altered gene regulation. Data remain scarce on how epigenetic variance contributes to disease risk in paediatric SLE (pSLE). We aim to identify differences in epigenetically regulated chromatin architecture in treatment-naive patients with pSLE compared with healthy children. METHODS: Using the assay for transposase-accessible chromatin with sequencing (ATACseq), we surveyed open chromatin in 10 treatment-naive patients with pSLE, with at least moderate disease severity, and 5 healthy children. We investigated whether regions of open chromatin unique to patients with pSLE demonstrate enrichment for specific transcriptional regulators, using standard computational approaches to identify unique peaks and a false discovery rate of <0.05. Further analyses for histone modification enrichment and variant calling were performed using bioinformatics packages in R and Linux. RESULTS: We identified 30 139 differentially accessible regions (DAR) unique to pSLE B cells; 64.3% are more accessible in pSLE than healthy children. Many DAR are found in distal, intergenic regions and enriched for enhancer histone marks (p=0.027). B cells from adult patients with SLE contain more regions of inaccessible chromatin than those in pSLE. In pSLE B cells, 65.2% of the DAR are located within or near known SLE haplotypes. Further analysis revealed enrichment of transcription factor binding motifs within these DAR that may regulate genes involved in pro-inflammatory responses and cellular adhesion. CONCLUSIONS: We demonstrate an epigenetically distinct profile in pSLE B cells when compared with healthy children and adults with lupus, indicating that pSLE B cells are predisposed for disease onset/development. Increased chromatin accessibility in non-coding genomic regions controlling activation of inflammation suggest that transcriptional dysregulation by regulatory elements controlling B cell activation plays an important role in pSLE pathogenesis. BMJ Publishing Group 2023-05-18 /pmc/articles/PMC10201247/ /pubmed/37202122 http://dx.doi.org/10.1136/lupus-2023-000921 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Genetics
Hui-Yuen, Joyce
Jiang, Kaiyu
Malkiel, Susan
Eberhard, Barbara Anne
Walters, Heather
Diamond, Betty
Jarvis, James
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
title B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
title_full B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
title_fullStr B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
title_full_unstemmed B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
title_short B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
title_sort b lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201247/
https://www.ncbi.nlm.nih.gov/pubmed/37202122
http://dx.doi.org/10.1136/lupus-2023-000921
work_keys_str_mv AT huiyuenjoyce blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren
AT jiangkaiyu blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren
AT malkielsusan blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren
AT eberhardbarbaraanne blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren
AT waltersheather blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren
AT diamondbetty blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren
AT jarvisjames blymphocytesintreatmentnaivepaediatricpatientswithlupusareepigeneticallydistinctfromhealthychildren